Raphael Levy
About Raphael Levy
Raphael Levy is the Associate Director of Antibody Discovery at Bristol Myers Squibb, with extensive experience in antibody engineering and immuno-oncology.
Current Role at Bristol Myers Squibb
Raphael Levy is currently serving as Associate Director, Antibody Discovery at Bristol Myers Squibb based in Redwood City, California, United States. In his role, Levy leads the Single B cell cloning Molecular Rescue team, which focuses on therapeutic and diagnostic targets. He also plays leading roles in multiple programs within the field of immuno-oncology and other indications.
Previous Role at LakePharma, Inc.
Prior to his current position, Raphael Levy worked at LakePharma, Inc. as the Director of Antibody Engineering. During his tenure from 2017 to 2021, he was responsible for overseeing various antibody engineering projects. His work involved significant contributions to the San Francisco Bay Area's biomedical engineering landscape.
Experience at XOMA (US) LLC
Raphael Levy spent a decade at XOMA (US) LLC in Berkeley, CA, where he progressed through various roles from Scientist I to Senior Scientist II. His tenure extended from 2006 to 2017, during which he developed his expertise significantly in antibody discovery and engineering. His roles included Scientist I (2006-2008), Scientist II (2008-2010), Senior Scientist I (2010-2016), and Senior Scientist II (2016-2017).
Educational Background
Raphael Levy's educational journey began at The Hebrew University of Jerusalem, Israel, where he earned a Bachelor of Science in Biology. He then obtained a Master of Science in Biotechnology from Tel Aviv University. Following this, Levy pursued his doctoral studies at The University of Texas at Austin, where he achieved a Doctor of Philosophy in Molecular Biology, completing it in six years from 1998 to 2004.
Early Career and Postdoctoral Work
After completing his Ph.D., Raphael Levy worked as a Postdoctoral Fellow at the University of California, San Francisco (UCSF) in the James Marks Laboratory from 2004 to 2006. During this period, he honed his research skills and expanded his knowledge in molecular biology and antibody engineering, laying a strong foundation for his subsequent roles in the biotech industry.